ArticleERJ open research2021
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.International journal of chronic obstructive pulmonary disease · 2022Trial
- Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness Analyses.PharmacoEconomics · 2026Review
- Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis.Pulmonary therapy · 2026Article
- Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS.Pharmacy (Basel, Switzerland) · 2025Article
- Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK.International journal of chronic obstructive pulmonary disease · 2025Article
- Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States.International journal of chronic obstructive pulmonary disease · 2024Article
- Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.Respiratory research · 2023Article
- Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.International journal of chronic obstructive pulmonary disease · 2023Article
- Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study.International journal of chronic obstructive pulmonary disease · 2023Article
- Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.BMC health services research · 2022Article
- Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain.International journal of chronic obstructive pulmonary disease · 2022Article
- Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial.ERJ open research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg) improved clinical outcomes
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.